High-Trauma Fractures Linked to Osteoporosis
Additional study describes algorithm predicting risk of hip fracture in older women
TUESDAY, Nov. 27 (HealthDay News) -- New research shows that high-trauma fractures in older individuals are associated with low bone mineral density and increase the risk of subsequent fractures, while a new clinical algorithm can help predict the five-year risk of hip fracture in postmenopausal women. These research findings are published in two studies in the Nov. 28 issue of the Journal of the American Medical Association.
In the first study, Dawn C. Mackey and colleagues at the San Francisco Coordinating Center, California Pacific Medical Center Research Institute, analyzed data from a total of 14,017 older U.S. adults to investigate the association between bone mineral density (measured by dual-energy x-ray absorptiometry) and risk of high-trauma fractures. The researchers found that high-trauma fractures were associated with low bone mineral density, and individuals sustaining high-trauma fractures were at an increased risk of subsequent high-trauma and low-trauma fractures.
In the second study, John Robbins, M.D., of the University of California at Davis in Sacramento, and colleagues analyzed data from 93,676 postmenopausal women to create a model predicting five-year risk of hip fracture, and then tested the model in 10,750 women with bone mass density measurements. Eleven factors were predictive of hip fracture within five years: age, self-reported health, physical activity, weight, height, race/ethnicity, history of fracture after age 54, parental hip fracture, current smoking, corticosteroid use and treated diabetes. Incorporation of these factors into an algorithm allowed the prediction of the five-year risk of hip fracture across ethnicities.
"Fractures previously defined as due to high trauma, such as those from a blunt injury in a motor vehicle crash or a fall from a chair, can no longer be dismissed as being unrelated to osteoporosis," writes the author of an associated editorial.
Several authors of both studies report receiving research support, consulting fees and other financial incentives from various pharmaceutical companies.